FORM 13-501F1
~~CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS –~~
PARTICIPATION FEE

MANAGEMENT CERTIFICATION

Chris Hopkins

I, _____, an officer of the reporting issuer noted below have examined this Form 13-501F1 (the **Form**) being submitted hereunder to the Alberta Securities Commission and certify that to my knowledge, having exercised reasonable diligence, the information provided in the Form is complete and accurate.

"Chris Hopkins"   January 29, 2020

Name: Chris Hopkins   Date:

Title: Chief Financial Officer

Relay Medical Corp.

Reporting Issuer Name: _____

September 30, 2019

End date of previous financial year: _____

Type of Reporting Issuer: [×] Class 1 reporting   [   ] Class 3B reporting
                                            issuer   issuer

CSE

Highest Trading Marketplace: _____

Market value of listed or quoted equity securities:

RELA

Equity Symbol _____

October 1, 2018   December 31, 2018

1st Specified Trading Period (dd/mm/yy)   _____ to _____

Closing price of the security in the class or series on the
last trading day of the specified trading period in which   0.23
such security was listed or quoted on the highest trading $ _____
marketplace   (i)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period

(ii)   113,187,191

Market value of class or series   (i) x (ii) $ 26,033,054
                                                        (A)

2nd Specified Trading Period (dd/mm/yy)   January1, 2019   to   March 31, 2019

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace

(iii) $ 0.22

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period

(iv)   113,187,191

Market value of class or series   (iii) x (iv) $ 24,901,182
                                                        (B)

3rd Specified Trading Period (dd/mm/yy)   April 1, 2019   to   June 30, 2019

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace

(v) $ 0.22

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period

(vi)   120,849,690

Market value of class or series   (v) x (vi) $ 26,586,932
                                                        (C)

4th Specified Trading Period (dd/mm/yy)

July 1, 2019 _____ to _____ September 30, 2019

Closing price of the security in the class or series on the
last trading day of the specified trading period in which
such security was listed or quoted on the highest trading
marketplace

$ _____ 0.215
(vii)

Number of securities in the class or series of such
security outstanding at the end of the last trading day of
the specified trading period

_____ 124,880,164
(viii)

Market value of class or series

(vii) x (viii) $ _____ 26,849,235
(D)

5th Specified Trading Period (dd/mm/yy)

_____ to _____

Closing price of the security in the class or series on the
last trading day of the specified trading period in which
such security was listed or quoted on the highest trading
marketplace

$ _____
(ix)

Number of securities in the class or series of such
security outstanding at the end of the last trading day of
the specified trading period

_____
(x)

Market value of class or series

(ix) x (x) $ _____
(E)

Average Market Value of Class or Series (Calculate
the simple average of the market value of the class or
series of security for each applicable specified trading
period (i.e. A through E above))

$ _____ 26,092,601
(1)

(Repeat the above calculation for each other class or series of equity securities of the reporting
issuer (and a subsidiary, if applicable) that was listed or quoted on a marketplace at the end of the
previous financial year)

Fair value of outstanding debt securities:

(Provide details of how value was determined)		$ _____ **(2)**
Capitalization for the previous financial year	(1) + (2)	$ _____
Participation Fee		$ _____
Late Fee, if applicable		$ _____
Total Fee Payable (Participation Fee plus Late Fee)		$ _____